Dr Reddys stock analysis shows bullish setup as technical indicators turn positive

Dr. Reddy's Laboratories shares are drawing attention around Maha Shivratri 2026, with technical signals turning positive. Choice Broking's Executive Director and Head of Technical Research, Sumeet Bagadia, sees scope for a fresh upside. Price action on the weekly chart suggests a possible bullish phase, with defined targets and support levels giving traders a clear framework.

Bagadia tracks DRREDDY near Rs 1270, where the risk-reward equation appears balanced for positional traders. Dips towards Rs 1245 are viewed as opportunities to build long exposure. A key support zone lies at Rs 1165, which acts as a technical line in the sand for the current bullish view.

On the weekly time frame, DRREDDY shows a strong rebound after testing the lower boundary of its price channel. This area is close to the 200-day exponential moving average, which often acts as dynamic support. The sharp recovery from these levels points to renewed demand and active buying interest from market participants.

A bullish engulfing candlestick pattern has formed near this support region, which usually signals a potential trend change. The stock has also moved above a falling trendline channel, indicating a shift in sentiment. DRREDDY now trades above its key EMAs, which are sloping higher, while the weekly RSI at 53.73 reflects firm momentum without overbought readings.

Bagadia recommends accumulating DRREDDY in the Rs 1270 to Rs 1245 band, with upside objectives at Rs 1375 and Rs 1465 in the medium term. The move above resistance levels, backed by steady volumes, suggests gradual accumulation by market players. As long as prices hold above Rs 1165, the structure appears supportive of a breakout-led advance.

Dr Reddy's share price target and Q3 FY26 earnings performance

The trading call comes after Dr. Reddy's reported mixed financials for the December FY26 quarter. Consolidated net profit stood at Rs 1,209.8 crore, which was 14.4% lower year-on-year than Rs 1,413.3 crore. However, revenue from operations rose 4.4% year-on-year to Rs 8,726.8 crore, compared with Rs 8,358.6 crore in Q3FY25.

Operating profit performance was weaker over the same period. EBITDA for the October-December FY26 quarter came in at Rs 2,049.3 crore. This was below the Q3FY25 EBITDA of Rs 2,298.2 crore, marking a 10.83% year-on-year decline. The combination of revenue growth and softer profit trends sets the backdrop for the current technical view.

Metric	Q3FY26	Q3FY25	YoY Change
Revenue from operations (Rs crore)	8,726.8	8,358.6	+4.4%
Consolidated net profit (Rs crore)	1,209.8	1,413.3	-14.4%
EBITDA (Rs crore)	2,049.3	2,298.2	-10.83%

Risk levels around Dr Reddy's share price target

The technical setup for DRREDDY remains constructive while prices stay above Rs 1165. A sustained move below this support could weaken the bullish case and open scope for further declines. Traders and investors are therefore watching this level closely, alongside the projected targets at Rs 1375 and Rs 1465, when planning any exposure.

For market participants, DRREDDY presents a situation where improving chart structure contrasts with softer quarterly profitability. The defined entry band, clear stop level, and specified targets offer transparency for strategy planning. Investors focused on pharmaceuticals may track how price behaviour and upcoming results interact with the current bullish indications.

"Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions."